Pages that link to "Q70524822"
Jump to navigation
Jump to search
The following pages link to Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy (Q70524822):
Displaying 50 items.
- Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia (Q24621923) (← links)
- Childhood acute myeloid leukaemia (Q27005960) (← links)
- Progress in acute myeloid leukemia (Q27024006) (← links)
- Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma (Q30240892) (← links)
- Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation (Q30311012) (← links)
- Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia (Q30622245) (← links)
- Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells (Q32173648) (← links)
- Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma (Q33341143) (← links)
- Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia (Q33345782) (← links)
- Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. (Q33499470) (← links)
- Basis for effective combination cancer chemotherapy with antimetabolites (Q33919546) (← links)
- Promising approaches in acute leukemia (Q33929477) (← links)
- Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies (Q33991278) (← links)
- Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival (Q34018590) (← links)
- Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies (Q34116907) (← links)
- Nucleoside analogues: mechanisms of drug resistance and reversal strategies. (Q34288371) (← links)
- Problems related to resistance to cytarabine in acute myeloid leukemia (Q34347446) (← links)
- Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia (Q34358512) (← links)
- The role of purine analogue combinations in the management of acute leukemias (Q34469145) (← links)
- Cellular and clinical pharmacology of fludarabine (Q34558562) (← links)
- The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients (Q34569051) (← links)
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia (Q34983843) (← links)
- Critical review on non-myeloablative stem cell transplantation (NST). (Q34987435) (← links)
- Update on non-myeloablative stem cell transplantation for hematologic malignancies (Q34996079) (← links)
- Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. (Q35278018) (← links)
- A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia (Q35296104) (← links)
- Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia (Q35546759) (← links)
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia (Q35606252) (← links)
- Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine (Q35847836) (← links)
- Purine analogs in leukemia (Q35909292) (← links)
- The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog (Q36085774) (← links)
- Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia (Q36152664) (← links)
- Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group (Q36407162) (← links)
- Ocular toxicity of fludarabine: a purine analog (Q36638487) (← links)
- Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells (Q36924097) (← links)
- The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia (Q37232078) (← links)
- A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (Q37304878) (← links)
- Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results (Q37372832) (← links)
- Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (Q37383528) (← links)
- RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. (Q37387162) (← links)
- A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms (Q37676277) (← links)
- High-dose cytarabine (HD araC) in the treatment of leukemias: a review (Q38108632) (← links)
- Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments (Q38155455) (← links)
- Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (Q38197075) (← links)
- Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. (Q38569175) (← links)
- Frontline treatment of acute myeloid leukemia in adults (Q38767583) (← links)
- The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines (Q39451195) (← links)
- Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia (Q39468003) (← links)
- Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. (Q39784049) (← links)
- Evolution of the Arabinosides and the Pharmacology of Fludarabine (Q40394290) (← links)